TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort study.
Biomarkers
COVID-19
CRP
Host response
IP-10
Point-of-care testing
Severity prediction
TRAIL
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
03
02
2022
revised:
08
04
2022
accepted:
22
05
2022
pubmed:
2
6
2022
medline:
9
9
2022
entrez:
1
6
2022
Statut:
ppublish
Résumé
Early prognostication of COVID-19 severity will potentially improve patient care. Biomarkers, such as TNF-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein 10 (IP-10), and C-reactive protein (CRP), might represent possible tools for point-of-care testing and severity prediction. In this prospective cohort study, we analyzed serum levels of TRAIL, IP-10, and CRP in patients with COVID-19, compared them with control subjects, and investigated the association with disease severity. A total of 899 measurements were performed in 132 patients (mean age 64 years, 40.2% females). Among patients with COVID-19, TRAIL levels were lower (49.5 vs 87 pg/ml, P = 0.0142), whereas IP-10 and CRP showed higher levels (667.5 vs 127 pg/ml, P <0.001; 75.3 vs 1.6 mg/l, P <0.001) than healthy controls. TRAIL yielded an inverse correlation with length of hospital and intensive care unit (ICU) stay, Simplified Acute Physiology Score II, and National Early Warning Score, and IP-10 showed a positive correlation with disease severity. Multivariable regression revealed that obesity (adjusted odds ratio [aOR] 5.434, 95% confidence interval [CI] 1.005-29.38), CRP (aOR 1.014, 95% CI 1.002-1.027), and peak IP-10 (aOR 1.001, 95% CI 1.00-1.002) were independent predictors of in-ICU mortality. We demonstrated a correlation between COVID-19 severity and TRAIL, IP-10, and CRP. Multivariable regression showed a role for IP-10 in predicting unfavourable outcomes, such as in-ICU mortality. Clinicaltrials.gov, NCT04655521.
Sections du résumé
BACKGROUND
BACKGROUND
Early prognostication of COVID-19 severity will potentially improve patient care. Biomarkers, such as TNF-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein 10 (IP-10), and C-reactive protein (CRP), might represent possible tools for point-of-care testing and severity prediction.
METHODS
METHODS
In this prospective cohort study, we analyzed serum levels of TRAIL, IP-10, and CRP in patients with COVID-19, compared them with control subjects, and investigated the association with disease severity.
RESULTS
RESULTS
A total of 899 measurements were performed in 132 patients (mean age 64 years, 40.2% females). Among patients with COVID-19, TRAIL levels were lower (49.5 vs 87 pg/ml, P = 0.0142), whereas IP-10 and CRP showed higher levels (667.5 vs 127 pg/ml, P <0.001; 75.3 vs 1.6 mg/l, P <0.001) than healthy controls. TRAIL yielded an inverse correlation with length of hospital and intensive care unit (ICU) stay, Simplified Acute Physiology Score II, and National Early Warning Score, and IP-10 showed a positive correlation with disease severity. Multivariable regression revealed that obesity (adjusted odds ratio [aOR] 5.434, 95% confidence interval [CI] 1.005-29.38), CRP (aOR 1.014, 95% CI 1.002-1.027), and peak IP-10 (aOR 1.001, 95% CI 1.00-1.002) were independent predictors of in-ICU mortality.
CONCLUSIONS
CONCLUSIONS
We demonstrated a correlation between COVID-19 severity and TRAIL, IP-10, and CRP. Multivariable regression showed a role for IP-10 in predicting unfavourable outcomes, such as in-ICU mortality.
TRIAL REGISTRATION
BACKGROUND
Clinicaltrials.gov, NCT04655521.
Identifiants
pubmed: 35643306
pii: S1201-9712(22)00315-0
doi: 10.1016/j.ijid.2022.05.051
pmc: PMC9132472
pii:
doi:
Substances chimiques
Chemokine CXCL10
0
TNF-Related Apoptosis-Inducing Ligand
0
Interferon-gamma
82115-62-6
C-Reactive Protein
9007-41-4
Banques de données
ClinicalTrials.gov
['NCT04655521']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
178-187Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors have no competing interests to declare.
Références
Scand J Trauma Resusc Emerg Med. 2019 Dec 16;27(1):111
pubmed: 31842961
Lancet Infect Dis. 2021 Nov;21(11):1485-1486
pubmed: 34506735
PLoS One. 2015 Mar 18;10(3):e0120012
pubmed: 25785720
Wien Med Wochenschr. 2020 Oct;170(13-14):357-358
pubmed: 32929620
JCI Insight. 2021 Jan 11;6(1):
pubmed: 33232303
Mol Med. 2020 Oct 29;26(1):97
pubmed: 33121429
Emerg Med J. 2021 Jul;38(7):543-548
pubmed: 34021028
J Clin Epidemiol. 2019 Aug;112:20-27
pubmed: 30930247
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620937175
pubmed: 32615866
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
Sci Transl Med. 2021 Sep 22;13(612):eabh2624
pubmed: 34429372
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
J Infect. 2020 Oct;81(4):607-613
pubmed: 32579983
Cytokine. 2021 Jun;142:155478
pubmed: 33667962
Clin Microbiol Infect. 2021 Jan;27(1):47-54
pubmed: 33190794
J Allergy Clin Immunol. 2020 Jul;146(1):119-127.e4
pubmed: 32360286
Cochrane Database Syst Rev. 2021 Mar 18;3:CD013881
pubmed: 33734435
Metabolism. 2020 Jul;108:154262
pubmed: 32422233
Int J Infect Dis. 2020 Dec;101:174-179
pubmed: 33002623
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Clin Chim Acta. 2020 Oct;509:135-138
pubmed: 32531257
Clin Microbiol Infect. 2022 May;28(5):723-730
pubmed: 34768022
Infection. 2021 Oct;49(5):1069-1070
pubmed: 34009635
PLoS One. 2021 Jan 12;16(1):e0245296
pubmed: 33434221
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
J Infect. 2020 Jun;80(6):646-655
pubmed: 32277967
Clin Chem. 2005 Dec;51(12):2333-40
pubmed: 16195357
J Exp Med. 2021 Jul 5;218(7):
pubmed: 33890986
Clin Microbiol Infect. 2021 Aug;27(8):1109-1117
pubmed: 34015535
Scand J Clin Lab Invest. 2021 Dec;81(8):679-686
pubmed: 34762008
Obesity (Silver Spring). 2020 Jul;28(7):1195-1199
pubmed: 32271993
J Allergy Clin Immunol. 2014 May;133(5):1456-8
pubmed: 24698314
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
N Engl J Med. 2021 Apr 22;384(16):1503-1516
pubmed: 33631066